Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 7.39B 6.43B 6.07B 5.52B 10.33B 708B 10.37B 72.59B 28.03B 360B 27.74B 27.13B 1,158B P/E 2026 *
-12.4x
P/E 2027 * -23.2x
Enterprise Value 7.28B 6.34B 5.98B 5.44B 10.18B 698B 10.23B 71.58B 27.64B 355B 27.35B 26.75B 1,142B EV / Sales 2026 *
7.9x
EV / Sales 2027 * 5.41x
Free-Float
99.05%
Yield 2026 *
-
Yield 2027 * -
1 day-4.94%
1 week-18.02%
Current month-26.38%
1 month-26.91%
3 months-40.04%
6 months-37.69%
Current year-43.83%
1 week 44.27
Extreme 44.27
55.5
1 month 44.27
Extreme 44.27
64.19
Current year 44.27
Extreme 44.27
86.74
1 year 44.27
Extreme 44.27
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 30/06/2012
Chief Executive Officer 64 31/12/2019
Director of Finance/CFO 64 30/04/2000
Director TitleAgeSince
Director/Board Member 64 12/12/2005
Director/Board Member 73 30/04/2002
Director/Board Member 64 24/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Others

Chief Technology Officer

110 0.0001%
31/08/26 Others

Executive/Senior Manager

58 0.0000%
31/08/26 Others

Founder

98 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-4.94%-18.02%-27.16%+3.40% 7.39B
+0.11%+2.71%+0.44%+26.85% 46.28B
-1.12%+1.78%+42.30%+27.55% 43.85B
-3.04%-6.29%+338.56%+515.97% 40.93B
-0.74%+1.25%+4.92%+67.98% 39.89B
-0.50%+0.67%+10.29%+41.28% 29.5B
-0.46%+4.22%+22.81%+139.44% 17.09B
-0.97%-10.17% - - 15.55B
-0.57%+8.12%+22.19%+38.68% 15.22B
-3.14%+31.91%-11.79% - 14.05B
Average -1.54%+1.58%+44.73%+107.64% 26.97B
Weighted average by Cap. -1.20%+1.33%+65.28%+126.98%

Financials

2026 *2027 *
Net sales 921M 803M 757M 688M 1.29B 88.33B 1.29B 9.06B 3.5B 44.91B 3.46B 3.38B 145B 1.38B 1.2B 1.13B 1.03B 1.93B 132B 1.94B 13.54B 5.23B 67.17B 5.18B 5.06B 216B
Net income -572M -498M -470M -427M -800M -54.83B -803M -5.62B -2.17B -27.88B -2.15B -2.1B -89.71B -320M -279M -263M -239M -447M -30.66B -449M -3.14B -1.21B -15.59B -1.2B -1.17B -50.17B
Net Debt -103M -89.71M -84.62M -76.94M -144M -9.87B -145M -1.01B -391M -5.02B -387M -378M -16.15B 68.31M 59.5M 56.12M 51.03M 95.51M 6.55B 95.94M 671M 259M 3.33B 257M 251M 10.71B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
18/09/26 US$44.44 -4.94% 7,369,358
17/09/26 US$46.75 +4.26% 4,079,573
16/09/26 US$44.84 -5.10% 7,958,214
15/09/26 US$47.25 -8.15% 6,812,465
14/09/26 US$51.44 -5.11% 5,974,753
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
44.44USD
Average target price
83.82USD
Spread / Average Target
+88.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!